Clin Cancer Res: Efficacy of olaparib maintenance monotherapy in Asian patients with platinum-sensitive recurrent ovarian cancer

Olaparib monotherapy maintenance therapy significantly prolongs progression-free survival (PFS) compared with placebo in patients with platinum-sensitive recurrent (PSR) ovarian cancer (OC)
.

This study is the first to evaluate the efficacy and tolerability of olaparib in Asian patients with platinum-sensitive recurrent ovarian cancer
.

This is an open-label, single-arm Phase 3 clinical trial recruiting a large number of patients with platinum-sensitive recurrent high-grade epithelial ovarian cancer from national clinical centers in China and Malaysia
.

Between 2018 and 2020, a total of 225 patients were recruited, of which 224 received olaparib; 35.
7% of patients had received ≥3 lines of chemotherapy, and 35.
3% of patients were platinum-based on the last line of patients achieved complete remission after chemotherapy, and 41.
1% of patients were enrolled ≥12 months after their last platinum-based drug use
.

Overall median progression-free survival

As of December 25, 2020, the overall median progression-free survival was 16.
1 months, and the median progression-free survival for patients with BRCA mutations and BRCA wild-type was 21.
2 months and 11.
0 months, respectively
.

Median progression-free survival in patients with different genotypes

99.
1% of patients experienced grade 3 or higher adverse events; 9.
4% of patients discontinued treatment due to treatment-related adverse events
.

In conclusion, maintenance therapy with olaparib had high therapeutic activity and was well tolerated in Asian patients with platinum-sensitive recurrent ovarian cancer , regardless of BRCA status
.

Original source:

Qinglei Gao, Jianqing Zhu, Weidong Zhao, et al.